P9 Comparison of cetuximab and bevacizumab as first-line treatment in KRAS wild type advanced colorectal cancer patients: a retrospective analysis

Line Treatment ◽

Wild Type ◽

First Line ◽

Comparison of Cetuximab and Bevacizumab as First-Line Treatment in KRAS Wild Type Advanced Colorectal Cancer Patients: A Retrospective Analysis

Annals of Oncology ◽

10.1093/annonc/mdu165.199 ◽

2014 ◽

Vol 25 ◽

pp. ii76

Author(s):

Zhang Qian ◽

Yau Thomas ◽

Leung Roland ◽

Wong Hilda ◽

Chiu Joanne ◽

...

Keyword(s):

Colorectal Cancer ◽

Retrospective Analysis ◽

Cancer Patients ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2018.03.003 ◽

2018 ◽

Vol 125 ◽

pp. 69-77 ◽

Cited By ~ 6

Author(s):

Domenico Ciliberto ◽

Nicoletta Staropoli ◽

Francesca Caglioti ◽

Silvia Chiellino ◽

Antonella Ierardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation

British Journal of Cancer ◽

10.1038/sj.bjc.6604121 ◽

2007 ◽

Vol 98 (1) ◽

pp. 71-76 ◽

Cited By ~ 28

Author(s):

S Cascinu ◽

R Berardi ◽

S Salvagni ◽

G D Beretta ◽

V Catalano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicentre Phase ◽

Faculty of 1000 evaluation for FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718009648.793485773 ◽

2013 ◽

Author(s):

Yiqian Nancy You ◽

Craig Messick

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox as a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece

Value in Health ◽

10.1016/j.jval.2014.08.2268 ◽

2014 ◽

Vol 17 (7) ◽

pp. A633 ◽

Cited By ~ 2

Author(s):

G. Kourlaba ◽

I. Boukovinas ◽

Z. Saridaki ◽

V. Papagiannopoulou ◽

G. Tritaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

Annals of Oncology ◽

10.1093/annonc/mdq261 ◽

2010 ◽

Vol 21 (12) ◽

pp. 2382-2389 ◽

Cited By ~ 72

Author(s):

M. Ronzoni ◽

M. Manzoni ◽

S. Mariucci ◽

F. Loupakis ◽

S. Brugnatelli ◽

...

Keyword(s):

Colorectal Cancer ◽

Endothelial Cells ◽

Clinical Response ◽

Cancer Patients ◽

Circulating Endothelial Cells ◽

Line Treatment ◽

First Line ◽

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Annals of Oncology ◽

10.1093/annonc/mdt165 ◽

2013 ◽

Vol 24 (8) ◽

pp. 2062-2067 ◽

Cited By ~ 67

Author(s):

L. Fornaro ◽

S. Lonardi ◽

G. Masi ◽

F. Loupakis ◽

F. Bergamo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Cost-Minimization Analysis of Panitumumab Compared with Cetuximab in the First-Line Treatment of Wild-Type RAS Metastatic Colorectal Cancer Patients in Brazil

Value in Health ◽

10.1016/j.jval.2016.09.2242 ◽

2016 ◽

Vol 19 (7) ◽

pp. A738-A739

Author(s):

RF dos Santos ◽

BS Riveros ◽

ME Nita ◽

GO Pedro

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Cost Minimization ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Cost Minimization Analysis ◽

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Annals of Oncology ◽

10.1093/annonc/mdw335.14 ◽

2016 ◽

Vol 27 ◽

pp. iv43

Author(s):

D. Rossini ◽

M. Casagrande ◽

R. Moretto ◽

F. Loupakis ◽

C. Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Pooled Analysis ◽

Line Treatment ◽

Targeted Agents ◽

First Line ◽

Safety And Efficacy ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

Colorectal Cancer Patients